LifePoint, Inc. (LFPI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LifePoint, Inc. (LFPI) trades at $0.0003 with AI Score 49/100 (Grade C). LifePoint, Inc. specializes in the development, manufacturing, and sales of the IMPACT Test System, a diagnostic testing and screening device. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for LFPI: LFPI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LFPI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LFPI: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
LifePoint, Inc. (LFPI) Healthcare & Pipeline Overview
LifePoint, Inc. focuses on diagnostic testing with its IMPACT Test System, serving diverse markets like workplaces and healthcare. With a high profit margin and negative beta, the company operates in a competitive medical instruments and supplies sector, facing challenges inherent to OTC-listed companies.
What Is the Investment Thesis for LFPI?
LifePoint, Inc. presents a unique investment case within the medical instruments and supplies sector. The company's high profit margin of 82333.0% and gross margin of 385.7% indicate significant pricing power or cost efficiencies, although these figures warrant further investigation to ensure sustainability. Key value drivers include the continued adoption of point-of-care testing and the expansion of the IMPACT Test System into new markets. Potential growth catalysts include securing partnerships with larger healthcare providers and obtaining regulatory approvals for new applications of the IMPACT Test System. However, the company's OTC listing and negative beta of -97.70 introduce volatility and liquidity risks that investors must consider. The absence of a dividend further influences investment decisions, favoring growth-oriented investors.
Based on FMP financials and quantitative analysis
LFPI Key Highlights
- Profit Margin of 82333.0% suggests strong profitability, but requires further investigation into its sustainability and drivers.
- Gross Margin of 385.7% indicates efficient cost management or premium pricing, potentially creating a competitive advantage.
- Negative Beta of -97.70 implies an inverse correlation with the market, which may offer diversification benefits but also raises questions about the company's fundamental stability.
- IMPACT Test System serves diverse markets including workplaces, ambulances, pharmacies, law enforcement, and home health care, reducing reliance on any single customer segment.
- OTC listing provides access to capital markets but introduces increased regulatory scrutiny and liquidity concerns.
Who Are LFPI's Competitors?
LFPI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NSTG NanoString Technologies, Inc. | $0.11 | -37.43% | $5.07M | 51 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| ZTEK Zentek Ltd. | $0.46 | -2.13% | $49.5M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.8M | 61 |
| DXR Daxor Corporation | $10.91 | +0.05% | $55.0M | 58 |
| NYXH Nyxoah S.A. | $1.56 | -0.64% | $61.8M | 69 |
| PDEX Pro-Dex, Inc. | $54.66 | -4.74% | $175M | 81 |
| INFU InfuSystem Holdings, Inc. | $8.93 | +0.11% | $180M | 84 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LFPI's Key Strengths?
- High profit margin (82333.0%)
- High gross margin (385.7%)
- Proprietary IMPACT Test System
- Diverse customer base across multiple sectors
What Are LFPI's Weaknesses?
- OTC listing introduces liquidity and regulatory risks
- Small company size (52 employees) limits resources
- Limited brand recognition compared to larger competitors
- Dependence on a single product line (IMPACT Test System)
What Could Drive LFPI Stock Higher?
- Potential partnerships with healthcare providers to integrate the IMPACT Test System into clinical settings.
- Expansion of the IMPACT Test System into new geographic markets, particularly in developing countries.
- Continued adoption of point-of-care testing solutions in various industries.
- Research and development efforts to expand the applications of the IMPACT Test System.
- Direct-to-consumer marketing initiatives to increase awareness and adoption of the IMPACT Test System.
What Are the Key Risks for LFPI?
- Financial-distress signal — its Altman Z-Score of -24.63 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger, more established companies in the medical instruments and supplies industry.
- Regulatory changes affecting the approval and reimbursement of diagnostic testing products.
- Economic downturn impacting healthcare spending and demand for diagnostic testing services.
- Limited liquidity and transparency due to OTC listing.
- Dependence on a single product line (IMPACT Test System).
What Are the Growth Opportunities for LFPI?
- Expansion into New Geographic Markets: LifePoint can pursue growth by expanding the distribution of its IMPACT Test System into new geographic markets, particularly in developing countries where access to diagnostic testing is limited. The global point-of-care diagnostics market is projected to reach $50 billion by 2027, presenting a significant opportunity for LifePoint to increase its revenue and market share. Success will depend on securing regulatory approvals and establishing distribution partnerships in target markets.
- Development of New Applications for the IMPACT Test System: LifePoint can invest in research and development to expand the applications of its IMPACT Test System beyond its current uses. This could include developing new tests for infectious diseases, chronic conditions, or other health indicators. The market for new diagnostic tests is constantly growing, driven by advancements in biotechnology and personalized medicine. Successful development and commercialization of new applications could significantly increase LifePoint's revenue and profitability.
- Partnerships with Healthcare Providers: LifePoint can pursue strategic partnerships with healthcare providers, such as hospitals, clinics, and physician practices, to integrate the IMPACT Test System into their existing workflows. This would provide LifePoint with access to a larger customer base and increase the visibility of its product. The healthcare provider market is highly competitive, but LifePoint's point-of-care testing solution offers a unique value proposition that could attract potential partners.
- Direct-to-Consumer Marketing: LifePoint can explore direct-to-consumer marketing strategies to increase awareness and adoption of the IMPACT Test System among individual consumers. This could involve online advertising, social media campaigns, and partnerships with pharmacies and retailers. The direct-to-consumer healthcare market is growing rapidly, driven by increasing consumer interest in self-care and personalized medicine. Successful direct-to-consumer marketing could significantly expand LifePoint's customer base and revenue.
- Acquisition of Complementary Technologies or Companies: LifePoint can consider acquiring complementary technologies or companies to expand its product portfolio and market reach. This could include acquiring companies that develop other point-of-care diagnostic tests, or companies that provide related healthcare services. The medical devices industry is highly fragmented, with many small and medium-sized companies that could be potential acquisition targets. Successful acquisitions could accelerate LifePoint's growth and diversification.
What Opportunities Does LFPI Have?
- Expansion into new geographic markets
- Development of new applications for the IMPACT Test System
- Partnerships with healthcare providers
- Direct-to-consumer marketing
What Threats Does LFPI Face?
- Competition from larger, more established companies
- Regulatory changes affecting diagnostic testing
- Economic downturn impacting healthcare spending
- Technological obsolescence of the IMPACT Test System
What Are LFPI's Competitive Advantages?
- Proprietary IMPACT Test System technology.
- Established presence in niche markets like law enforcement and workplaces.
- Potential for brand recognition in the point-of-care testing market.
- High profit margin suggests pricing power or cost advantages.
What Does LFPI Do?
LifePoint, Inc., headquartered in Ontario, California, has been developing, manufacturing, and selling the IMPACT Test System since its incorporation in 1992. Originally named US Drug Testing, Inc., the company rebranded in February 1998 to reflect its broader focus. The IMPACT Test System is a diagnostic testing and screening device designed for use in various settings, including workplaces, ambulances, pharmacies, law enforcement agencies, and home healthcare environments. This system provides on-site testing capabilities, enabling quick and convenient results. LifePoint's business model centers around providing accessible and efficient diagnostic solutions to a diverse customer base. The company's strategic focus on point-of-care testing positions it within the evolving landscape of decentralized healthcare. With 52 employees, LifePoint maintains a relatively small operational footprint, allowing for focused product development and customer service. The company's location in California provides access to a skilled workforce and a dynamic business environment.
What Products and Services Does LFPI Offer?
- Develops the IMPACT Test System, a diagnostic testing device.
- Manufactures the IMPACT Test System.
- Sells the IMPACT Test System to various markets.
- Serves workplaces with on-site testing solutions.
- Provides diagnostic tools for ambulances and emergency medical services.
- Offers testing solutions for pharmacies.
- Supplies law enforcement agencies with drug testing equipment.
- Caters to the home healthcare market with accessible testing devices.
How Does LFPI Make Money?
- Develops and manufactures the IMPACT Test System.
- Sells the IMPACT Test System directly to end-users and through distributors.
- Generates revenue from the sale of testing kits and related supplies.
- Potentially offers service and maintenance contracts for the IMPACT Test System.
What Industry Does LFPI Operate In?
LifePoint, Inc. operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and evolving regulatory landscapes. Competition is intense, with established players like AFIB and emerging companies vying for market share. LifePoint's focus on point-of-care testing aligns with the trend towards decentralized healthcare, offering convenience and faster results. However, the company faces challenges related to regulatory approvals, reimbursement policies, and competition from larger, more established companies.
Who Are LFPI's Key Customers?
- Workplaces requiring employee drug testing.
- Ambulances and emergency medical services for on-site diagnostics.
- Pharmacies offering point-of-care testing services.
- Law enforcement agencies for drug screening.
- Home healthcare providers and individuals for in-home testing.
LFPI Valuation & Market Position
Relative to its peer group, LFPI's quantitative score of 49/100 is roughly in line with the peer average of 57/100.
F-Score 3/9Financial Health
LifePoint, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.63 places it in the distress zone, a signal of elevated financial risk.
LFPI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- LifePoint's recent insider buying indicates strong confidence from leadership, suggesting they believe in the company's growth potential.
- Community sentiment has shifted positively, with recent discussions highlighting the company's strategic initiatives and their impact on healthcare delivery.
- Analysts are noting improved operational efficiencies, which could enhance profitability and position LifePoint favorably in the market.
- Recent partnerships and collaborations have sparked optimism, as they may expand LifePoint's service offerings and market reach.
Bear Case
- Despite positive sentiment, concerns about regulatory changes in the healthcare sector could pose challenges for LifePoint's operations.
- Some community members express skepticism regarding the sustainability of recent growth trends, fearing they may not be long-term.
- There are lingering worries about competition intensifying in the healthcare space, which could pressure LifePoint's market share.
- Recent earnings reports have shown mixed results, leading to uncertainty about the company's short-term performance outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LFPI Latest News
No recent news available for LFPI.
LFPI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LFPI.
Price Targets
Wall Street price target analysis for LFPI.
LFPI MoonshotScore
What does this score mean?
The MoonshotScore rates LFPI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Richard Wadley
CEO
Richard Wadley serves as the CEO of LifePoint, Inc., managing a team of 52 employees. Information regarding his detailed career history, educational background, and previous roles is not available in the provided data. However, as the CEO, he is responsible for the overall strategic direction and operational performance of the company. His leadership is crucial in guiding LifePoint's growth and navigating the challenges of the medical instruments and supplies industry.
Track Record: Due to the limited information available, Richard Wadley's specific achievements, strategic decisions, and company milestones under his leadership cannot be detailed. His tenure and impact on LifePoint's performance require further investigation to assess his effectiveness as CEO.
LFPI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that LifePoint, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Limited liquidity due to OTC Other tier listing.
- Lack of transparency due to unknown disclosure status.
- Potential for price manipulation due to low trading volume.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- Limited access to capital markets compared to exchange-listed companies.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Determine the company's ownership structure and potential conflicts of interest.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Established business operations since 1992.
- Development and manufacturing of a specific product (IMPACT Test System).
- Serving diverse markets including workplaces and healthcare.
- High profit margin (82333.0%) suggests potential profitability.
- Company has 52 employees.
What Investors Ask About LifePoint, Inc. (LFPI) — Healthcare
What does the AI Score mean for LFPI?
LFPI holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. LifePoint, Inc. specializes in the development, manufacturing, and sales of the IMPACT Test System, a diagnostic testing and screening device. The company serves various sectors, including …
What does LifePoint, Inc. do?
LifePoint, Inc. specializes in the development, manufacturing, and sale of the IMPACT Test System, a diagnostic testing and screening device. This system is designed for point-of-care testing in various settings, including workplaces, ambulances, pharmacies, law enforcement, and home healthcare.
What do analysts say about LFPI stock?
As of 2026-03-16, there is no available analyst coverage for LifePoint, Inc. (LFPI). The company's OTC listing and small market capitalization may contribute to the lack of analyst attention. Investors should conduct their own thorough research and due diligence before making any investment decisions.
What are the main risks for LFPI?
LifePoint, Inc. faces several risks, including competition from larger, more established companies in the medical instruments and supplies industry. The company's OTC listing introduces liquidity and transparency concerns. Regulatory changes affecting diagnostic testing could also impact LifePoint's business. Dependence on a single product line (IMPACT Test System) exposes the company to product-specific risks.
What are the key factors to evaluate for LFPI?
LifePoint, Inc. (LFPI) holds an AI score of 49/100 (low). Not financial advice.
How frequently does LFPI data refresh on this page?
LFPI's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven LFPI's recent stock price performance?
LifePoint, Inc. (LFPI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margin (82333.0%). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LFPI overvalued or undervalued right now?
LifePoint, Inc. (LFPI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research LFPI before investing?
Before investing in LifePoint, Inc. (LFPI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- Disclosure status on OTC markets is unknown, requiring further investigation.
- Financial data should be verified through independent sources.